US Patent 11408889 Anti-GITR antibodies for cancer diagnostics
Patent 11408889 was granted and assigned to Bristol-Myers Squibb on August, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 1 Nov, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 29 Apr, 2023
Golden AI
Infobox
Patent Citations
Golden AI
Edits on 1 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
114088890
Date of Patent
August 9, 2022
0Patent Application Number
168700060
Date Filed
May 8, 2020
0Patent Citations
0
Patent Primary Examiner
CPC Code
Edits on 25 Mar, 2023
Golden AI
Edits on 28 Sep, 2022
Golden AI
Edits on 25 Sep, 2022
Golden AI
Golden AI
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
114088890
Date of Patent
August 9, 2022
0Patent Application Number
168700060
Date Filed
May 8, 2020
0Patent Citations
0
Patent Primary Examiner
CPC Code
Edits on 22 Sep, 2022
Golden AI
Edits on 10 Aug, 2022
Golden AI
Edits made to:
Infobox (+15 properties)
Article (+399 characters)
US Patent 11408889 Anti-GITR antibodies for cancer diagnostics
Article
Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11408889
Date of patent
August 9, 2022
Patent application number
16870006
Date Filed
May 8, 2020
Patent citations
Patent primary examiner
CPC Code
Find more entities like US Patent 11408889 Anti-GITR antibodies for cancer diagnostics
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
